On July 3, 3SBio rose 6.67% in regular trading, trading at 19.06 HKD/share with turnover of 236 million HKD, extending the prior session's strong momentum.

On the policy front, the National Medical Insurance Bureau published preliminary review results for the medical insurance directory, with 557 drugs passing the review and 54 passing the commercial insurance innovative drug directory review, marking the substantive advancement of a dual medical-commercial insurance negotiation mechanism. New mechanisms including pre-declaration procedures and 8-year price protection have simultaneously been implemented, providing more stable policy expectations for innovative drug commercialization.

On the corporate front, the company conducted buybacks on three consecutive days in June (June 22, 25, 26), repurchasing approximately 8.52 million shares for a total of approximately 135 million HKD at prices ranging from 15.52 to 16.00 HKD per share. Chairman Lou Jing purchased 516,000 shares on June 8 for approximately 7.87 million HKD, while Huatai-PineBridge Fund acquired 636,500 shares on June 10. The broader biotech sector showed concurrent strength, with BeiGene up 5.04%, Remegen up 5.43%, and Akeso up 4.17%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)